Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company, announced on Wednesday that it has named Mark G Barberio as its new director.
Barberio has also been appointed to the company's Audit and Nominating and Governance Committees.
Barberio is the principal of Markapital LLC. Prior to founding Markapital, he led Mark IV LLC where he served in a number of leadership positions, including as its co-chief executive officer and chief financial officer.
Paul Campanelli, Endo's chairman, president and chief executive officer, said 'In addition to Mark's senior executive leadership experience, Mark's operations, finance and strategic planning perspective on corporate growth will provide valuable insight to the board. We are pleased to welcome him to our board.'
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream